List of Excipients in Branded Drug ONIVYDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Ipsen Biopharmaceuticals Inc	ONIVYDE	irinotecan hydrochloride	15054-0043	1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE
Ipsen Biopharmaceuticals Inc	ONIVYDE	irinotecan hydrochloride	15054-0043	CHOLESTEROL
Ipsen Biopharmaceuticals Inc	ONIVYDE	irinotecan hydrochloride	15054-0043	HYDROXYETHYLPIPERAZINE ETHANE SULFONIC ACID
Ipsen Biopharmaceuticals Inc	ONIVYDE	irinotecan hydrochloride	15054-0043	SODIUM CHLORIDE
Ipsen Biopharmaceuticals Inc	ONIVYDE	irinotecan hydrochloride	15054-0043	SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE

ONIVYDE Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

ONIVYDE is a pegylated liposomal irinotecan product whose commercial value depends on more than the active pharmaceutical ingredient. Its excipient system controls irinotecan loading, circulation time, release, tissue distribution, stability, and manufacturing reproducibility. The core commercial opportunity is in supplying pharmaceutical-grade lipids, PEG-lipid components, sterile injectable materials, analytical services, and competing nanomedicine platforms. The main barriers are formulation know-how, complex injectable manufacturing, regulatory comparability, and product-specific intellectual property.

What is ONIVYDE and how does its formulation work?

ONIVYDE is a liposomal formulation of irinotecan hydrochloride trihydrate marketed as irinotecan liposome injection. Ipsen markets the product in the United States after acquiring Merrimack Pharmaceuticals' oncology assets. The FDA first approved ONIVYDE in 2015 with fluorouracil and leucovorin for patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based therapy. In February 2024, the FDA expanded the indication to include ONIVYDE with oxaliplatin, leucovorin, and fluorouracil as a first-line treatment for metastatic pancreatic adenocarcinoma [1,2].

The product is administered intravenously and is supplied as a 43 mg irinotecan free-base equivalent in a 10 mL single-dose vial. The irinotecan is encapsulated in liposomes composed of phospholipid, cholesterol, and a PEGylated lipid. The formulation is designed to alter irinotecan pharmacokinetics and extend exposure relative to conventional irinotecan injection [1].

What excipients are used in ONIVYDE?

The principal ONIVYDE excipients are:

Excipient	Functional role	Commercial relevance
DSPC, or 1,2-distearoyl-sn-glycero-3-phosphocholine	Structural phospholipid forming the liposomal bilayer	Requires high-purity, injectable-grade supply
Cholesterol	Controls membrane packing, rigidity, permeability, and drug retention	Commodity availability is broad, but parenteral-grade quality is critical
DSPE-PEG2000, a PEGylated phospholipid	Provides steric stabilization and reduces rapid uptake by the reticuloendothelial system	High-value specialty lipid with narrower supplier base
Sucrose	Cryo- or lyoprotective and tonicity-supporting excipient	Supports liposome stability during processing and storage
HEPES	Buffering agent used to control formulation pH	Creates a specific injectable-grade sourcing and regulatory requirement
Sodium chloride	Tonicity adjustment	Lower differentiation but important for injectable quality
Water for injection	Vehicle	Standard sterile manufacturing input

The FDA prescribing information identifies sucrose, DSPC, cholesterol, DSPE-PEG2000, HEPES, sodium chloride, and water for injection as formulation components. The finished product has a target pH near physiological range [1].

The formulation uses a drug-loading strategy based on irinotecan encapsulation within liposomes. The excipients are therefore part of the product's performance architecture. Substituting one lipid, changing the PEG-lipid concentration, or altering the internal buffer can affect particle size, encapsulation efficiency, drug leakage, release kinetics, aggregation, sterility, and pharmacokinetics.

Why are ONIVYDE excipients commercially important?

The highest-value excipient opportunities are in specialized lipids rather than conventional formulation additives.

DSPC supply and manufacturing

DSPC is a saturated phospholipid used to form a stable bilayer. Its long, saturated acyl chains support membrane rigidity and reduce premature drug leakage. Commercial suppliers can compete through:

• Consistent fatty-acid composition
• Low peroxide and lysophospholipid levels
• Low endotoxin and bioburden
• Pharmaceutical-grade documentation
• Batch-to-batch control of purity and polymorphic behavior
• Scalable production under GMP conditions

DSPC is commercially available from multiple lipid manufacturers, which limits pricing power compared with proprietary PEG-lipid materials. The main opportunity is qualification as an approved or secondary source. Once a supplier is qualified for a complex liposomal product, switching costs are high because the sponsor must demonstrate that the replacement does not change critical quality attributes.

DSPE-PEG2000 as the highest-value excipient

DSPE-PEG2000 is the most strategically important excipient in the ONIVYDE system. It combines a phospholipid anchor with a PEG chain. The lipid portion remains in the bilayer while PEG provides a hydrated surface layer that can reduce aggregation and prolong circulation.

Commercial opportunities include:

• Pharmaceutical-grade DSPE-PEG2000
• Controlled PEG molecular-weight distribution
• Low residual solvent and low free PEG
• Oxidation-resistant packaging
• GMP manufacturing and validated impurity methods
• Supply-chain redundancy for clinical and commercial production

DSPE-PEG2000 is more difficult to replace than cholesterol or sodium chloride. Variations in PEG chain distribution, lipid purity, hydrolysis, oxidation, and incorporation efficiency can produce meaningful changes in liposome behavior. Suppliers with analytical packages covering lipid identity, free PEG, hydrolyzed lipid, oxidation products, residual solvents, and particle-related impurities have a stronger position.

PEG-lipid suppliers also face long-term strategic risk from the pharmaceutical industry's interest in non-PEG alternatives. Anti-PEG antibodies, accelerated blood clearance, and repeat-dose tolerability concerns have encouraged research into zwitterionic, polysarcosine, poly(2-oxazoline), and other stealth-coating systems. Those technologies create future platform opportunities, but they are not direct drop-in replacements for ONIVYDE without extensive formulation and clinical work.

What formulation attributes must an ONIVYDE competitor match?

A competing product would need to establish comparability across several quality attributes:

Attribute	Why it matters
Mean particle size and size distribution	Influences biodistribution, clearance, and safety
Zeta potential or surface characteristics	Affects aggregation and biological interactions
Irinotecan loading	Controls dose uniformity and potency
Encapsulation efficiency	Determines free versus liposomal drug
Lipid composition and molar ratios	Controls bilayer structure and release
PEG-lipid incorporation	Influences circulation and uptake
Free irinotecan and free lipid	Affects exposure and tolerability
In vitro release profile	Supports product performance comparison
Morphology and lamellarity	Provides evidence of structural similarity
pH, osmolality, and viscosity	Affects administration and stability
Sterility, endotoxin, and particulate matter	Required for injectable products
Stability after dilution	Important for pharmacy handling and administration

For a liposomal irinotecan product, conventional small-molecule bioequivalence logic is insufficient by itself. A sponsor may need a combination of physicochemical characterization, in vitro release testing, pharmacokinetic comparison, and clinical evidence. The regulatory pathway depends on the product's formulation, manufacturing process, and the extent of similarity to the reference product.

What commercial opportunities exist for ONIVYDE excipients?

1. Primary and secondary lipid supply

The strongest near-term opportunity is qualification as a secondary supplier of DSPC, cholesterol, or DSPE-PEG2000. ONIVYDE is a commercial product with an expanding treatment position in metastatic pancreatic cancer, increasing the value of supply continuity.

A secondary supplier must overcome:

• Sponsor qualification requirements
• GMP audit requirements
• Lipid-specific analytical validation
• Change-control restrictions
• Stability comparability
• Regulatory filing obligations
• Long lead times for process validation

A supplier with only catalog-grade material has limited commercial value. The target market is pharmaceutical-grade material with a full regulatory support package.

2. Custom lipid manufacturing

Custom synthesis is attractive for DSPE-PEG2000 and related PEGylated phospholipids. Contract manufacturers can compete by offering:

• Small-scale material for formulation development
• GMP clinical-trial batches
• Commercial-scale production
• Process impurity controls
• Regulatory support
• Locked supply capacity

The opportunity expands beyond ONIVYDE because the same lipid platform is used in liposomal oncology products, nucleic-acid delivery systems, vaccine formulations, and other nanomedicines.

3. Liposome process equipment and contract manufacturing

ONIVYDE requires controlled lipid dissolution, drug loading, size reduction, sterile filtration or aseptic processing, filling, and release testing. Contract development and manufacturing organizations can sell capacity for:

• High-shear mixing
• Microfluidic or impingement-jet mixing
• Membrane extrusion
• Tangential-flow filtration
• Aseptic filling
• Liposomal drug-loading processes
• In-process particle-size monitoring

The most defensible opportunity is not generic sterile filling. It is specialized capacity for complex liposomal injectables with validated control of size distribution, encapsulation, free drug, and release.

4. Analytical services

Liposomal products require more extensive characterization than conventional injectable solutions. Laboratories can provide testing for:

• Encapsulated versus free irinotecan
• Lipid degradation
• Particle size and polydispersity
• Morphology
• Drug-release kinetics
• PEG-lipid content
• Residual solvents
• Oxidation and hydrolysis products
• Dilution stability
• Container-closure compatibility

Analytical vendors that can support regulatory submissions have stronger pricing power than laboratories limited to routine release testing.

5. Improved storage and administration formats

ONIVYDE is supplied as a liquid concentrate requiring dilution before infusion. Commercial development opportunities include:

• Improved vial and stopper systems
• Lower adsorption packaging
• Longer in-use stability
• Reduced preparation time
• Closed-system transfer devices
• Ready-to-administer presentations
• Reduced-volume infusion formats

Any change to the primary container or administration method must preserve liposome integrity and demonstrate compatibility with the product. A ready-to-use presentation could reduce pharmacy labor and handling risk, but it would require substantial stability and regulatory work.

What formulation patents protect ONIVYDE?

ONIVYDE's protection is expected to involve multiple layers rather than a single excipient patent:

1. Liposomal irinotecan composition claims.
2. Lipid-ratio and drug-loading claims.
3. Methods for treating pancreatic cancer.
4. Dosing regimens using fluorouracil and leucovorin.
5. Combination regimens incorporating oxaliplatin.
6. Manufacturing and encapsulation processes.
7. Stability, administration, or use-related claims.

Merrimack developed the liposomal irinotecan technology, and Ipsen acquired the commercial oncology business and related rights. The best-known patent family associated with liposomal irinotecan includes U.S. Patent No. 8,147,867, covering liposomal irinotecan compositions. Patent term and current enforceability depend on patent-term adjustment, terminal disclaimers, PTA calculations, maintenance fees, reexamination history, and jurisdiction-specific prosecution records.

The excipient composition itself may be difficult to design around if the relevant claims require specific combinations of irinotecan, phospholipid, cholesterol, PEG-lipid, and loading characteristics. A competitor could attempt to avoid composition claims through:

• Alternative phospholipids
• Non-PEG surface coatings
• Different internal loading salts
• Different lipid molar ratios
• Non-liposomal nanocarriers
• Polymer or albumin-based delivery systems
• Alternative irinotecan prodrug approaches

Those approaches would create new development and clinical risks. A technically distinct product may avoid one patent family but still face method-of-use, formulation, or manufacturing claims.

What is the FDA regulatory status of ONIVYDE?

ONIVYDE is FDA-approved for two principal metastatic pancreatic cancer settings:

FDA milestone	Date	Significance
Original FDA approval	October 22, 2015	Approval with fluorouracil and leucovorin after gemcitabine-based therapy
First-line approval	February 13, 2024	Approval with oxaliplatin, leucovorin, and fluorouracil for metastatic disease

The 2024 approval was supported by the NAPOLI 3 study, which evaluated the multidrug regimen in previously untreated metastatic pancreatic adenocarcinoma [2]. The expanded indication increases the addressable treatment population and strengthens the commercial importance of the liposomal delivery system.

ONIVYDE is a complex injectable drug, not a conventional immediate-release tablet. Generic competition therefore faces formulation-specific regulatory challenges. A potential applicant must show that its product has comparable critical quality attributes and clinical performance. The regulatory burden can delay entry even when the underlying active ingredient is long established.

What generic entry risks exist for ONIVYDE?

The largest generic-entry risks are formulation and manufacturing risks.

Product-specific risks

A competitor must reproduce or sufficiently match:

• Liposome size distribution
• Irinotecan encapsulation
• Drug release
• Lipid composition
• PEG-lipid surface density
• Free-drug fraction
• Storage stability
• Dilution stability
• Infusion performance

Small process changes can affect these properties. The use of common excipients does not make the product easy to copy because the manufacturing process determines the final nanostructure.

Paragraph IV and patent litigation

A generic applicant could challenge listed patents through an abbreviated pathway and file a Paragraph IV certification. The commercial risk would depend on:

• The patents listed in the FDA Orange Book
• Their expiration dates and pediatric extensions
• The scope of composition and method claims
• Whether the generic's formulation practices fall within asserted claims
• Patent litigation and any 30-month stay
• Settlement terms and authorized-generic arrangements

An excipient supplier is generally not the principal target of such litigation, but its material specifications can become relevant to infringement, process similarity, or freedom-to-operate analysis. Suppliers should avoid copying proprietary manufacturing processes and should maintain independent process documentation.

How strong is the ONIVYDE patent estate?

The estate is strongest where formulation, delivery, and clinical-use claims overlap. A product that uses the same irinotecan liposome architecture may face a higher risk than one using a different delivery platform.

Patent protection layer	Relative strategic value
Liposomal irinotecan composition	High
Defined lipid ratios	High if claims are narrow and technically limiting
Manufacturing process	Medium to high, depending on claim scope and detectability
Method of treating pancreatic cancer	Medium to high for labeled indications
Combination regimen	Medium, with potential carve-out issues
General excipient claims	Usually lower unless tied to product performance
Trade secrets and know-how	High practical value even after patent expiry

Trade secrets may include loading conditions, mixing order, temperature control, filtration parameters, in-process testing, and scale-up methods. These assets can preserve manufacturing advantages after composition patents expire.

What happens when ONIVYDE loses exclusivity?

Patent expiry does not automatically produce immediate, low-cost competition. Liposomal injectables often experience slower market entry than conventional generics because applicants need validated manufacturing capacity, specialized analytical methods, and regulatory confidence.

Potential launch scenarios include:

1. A first complex generic enters after resolving formulation and patent barriers.
2. A 505(b)(2) applicant launches a modified liposomal irinotecan product with new clinical or administration claims.
3. A non-liposomal irinotecan competitor targets the same treatment setting but does not provide equivalent exposure.
4. An authorized generic or licensed product limits price erosion.
5. No near-term substitute enters because manufacturing economics are unattractive.

The commercial effect on Ipsen would depend on the share of ONIVYDE sales generated by the protected first-line indication, the timing of generic approvals, payer substitution, and the number of competing products. The 2024 label expansion increases the value of the product but can also increase the incentive for generic and biosimilar-style complex-drug development.

How does ONIVYDE compare with conventional irinotecan?

Attribute	ONIVYDE	Conventional irinotecan
Delivery system	Pegylated liposome	Aqueous injectable solution
Active drug	Irinotecan	Irinotecan
Excipients	Specialized lipid and PEG-lipid system	Conventional injectable excipients
Manufacturing complexity	High	Lower
Regulatory copying burden	High	More established
Pharmacokinetic objective	Prolonged exposure and altered distribution	Immediate systemic availability
Commercial differentiation	Formulation and clinical regimen	Active ingredient and dosing
Supply-chain opportunity	Lipids, nanomedicine manufacturing, analytics	Standard injectable manufacturing

ONIVYDE's differentiation is primarily delivery-based. The excipients are not passive ingredients. They create the product's pharmacokinetic and clinical profile.

What manufacturing and IP barriers affect commercial entrants?

The principal barriers are:

• Specialized lipid sourcing
• Aseptic processing at commercial scale
• Control of particle-size distribution
• Reproducible irinotecan loading
• Stability of PEGylated lipids
• Quantification of free and encapsulated drug
• Scale-up without changing release behavior
• Container-closure compatibility
• Regulatory comparability
• Patent and trade-secret clearance

Geographically, the strongest opportunities are in the United States, Europe, Japan, and China, where oncology demand and complex-injectable infrastructure are established. China and India offer potential cost advantages in lipid synthesis and contract manufacturing, but suppliers must meet the documentation, inspection, and regulatory standards required for U.S. and European commercialization.

Key Takeaways

• ONIVYDE's core excipient strategy uses DSPC, cholesterol, DSPE-PEG2000, sucrose, HEPES, sodium chloride, and water for injection.
• DSPE-PEG2000 is the most differentiated and commercially valuable excipient in the formulation.
• Secondary-source qualification for pharmaceutical-grade lipids is a realistic near-term opportunity.
• Liposome manufacturing, analytical characterization, and sterile fill-finish offer higher-value opportunities than commodity excipient supply.
• Generic entry is technically difficult because the liposome structure, drug loading, release profile, and manufacturing process must be controlled together.
• ONIVYDE's 2024 first-line pancreatic cancer approval expanded its commercial market and increased the value of its formulation platform.
• Patent expiry alone may not produce rapid competition because manufacturing know-how and regulatory comparability remain significant barriers.
• Alternative PEG-free and non-liposomal irinotecan platforms represent longer-term competitive opportunities, not simple excipient substitutions.

FAQs

Is DSPE-PEG2000 interchangeable with another PEGylated lipid in ONIVYDE?

No. Substitution can change particle size, circulation time, drug leakage, immune recognition, and pharmacokinetics. It would require formulation redevelopment and regulatory comparability work.

Can a pharmaceutical company buy ONIVYDE excipients from a catalog supplier?

Catalog-grade material is generally insufficient for commercial injectable use. A supplier must provide pharmaceutical-grade specifications, GMP documentation, impurity controls, and supply-chain support.

Does cholesterol have the same strategic value as DSPE-PEG2000?

No. Cholesterol is important for membrane stability, but it is more broadly available. DSPE-PEG2000 has greater differentiation because its purity and surface-stabilization function are closely linked to liposome performance.

Is ONIVYDE eligible for a conventional generic approval?

A conventional abbreviated application may be possible, but the product's complex liposomal structure creates additional equivalence and characterization requirements compared with a standard small-molecule injection.

What is the most attractive commercial entry point around ONIVYDE?

The strongest entry points are GMP DSPE-PEG2000, validated secondary lipid supply, liposomal-drug analytical testing, and contract manufacturing for complex sterile nanomedicines.

References

1. U.S. Food and Drug Administration. (2024). ONIVYDE (irinotecan liposome injection) prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2024, February 13). FDA approves first-line treatment for metastatic pancreatic adenocarcinoma. https://www.fda.gov
3. Ipsen Biopharmaceuticals, Inc. (2024). ONIVYDE product information and corporate oncology portfolio materials. https://www.ipsen.com
4. U.S. Patent No. 8,147,867. (2012). Liposomal compositions of irinotecan. United States Patent and Trademark Office.